These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 23563570)
1. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers. Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570 [TBL] [Abstract][Full Text] [Related]
2. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines. Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843 [TBL] [Abstract][Full Text] [Related]
3. 2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth. Chuang JH; Chou MH; Tai MH; Lin TK; Liou CW; Chen T; Hsu WM; Wang PW Int J Biochem Cell Biol; 2013 May; 45(5):944-51. PubMed ID: 23395630 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma. Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373 [TBL] [Abstract][Full Text] [Related]
5. Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine. Prochazka P; Hrabeta J; Vícha A; Eckschlager T Cancer Genet Cytogenet; 2010 Jan; 196(1):96-104. PubMed ID: 19963143 [TBL] [Abstract][Full Text] [Related]
6. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881 [TBL] [Abstract][Full Text] [Related]
7. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Paffhausen T; Schwab M; Westermann F Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950 [TBL] [Abstract][Full Text] [Related]
8. Microarray data analysis of neuroblastoma: Expression of SOX2 downregulates the expression of MYCN. Bao J; Qin L; Cui L; Wang X; Meng Q; Zhu L; Zhang S Mol Med Rep; 2015 Nov; 12(5):6867-72. PubMed ID: 26398570 [TBL] [Abstract][Full Text] [Related]
9. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167 [TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line. Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372 [TBL] [Abstract][Full Text] [Related]
11. Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. Bedrnicek J; Vicha A; Jarosova M; Holzerova M; Cinatl J; Michaelis M; Cinatl J; Eckschlager T Neoplasma; 2005; 52(5):415-9. PubMed ID: 16151587 [TBL] [Abstract][Full Text] [Related]
12. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections. Thorner PS; Ho M; Chilton-MacNeill S; Zielenska M Am J Surg Pathol; 2006 May; 30(5):635-42. PubMed ID: 16699319 [TBL] [Abstract][Full Text] [Related]
13. Concomitant DDX1 and MYCN gain in neuroblastoma. Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020 [TBL] [Abstract][Full Text] [Related]
14. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model. Blanc E; Goldschneider D; Ferrandis E; Barrois M; Le Roux G; Leonce S; Douc-Rasy S; Bénard J; Raguénez G Am J Pathol; 2003 Jul; 163(1):321-31. PubMed ID: 12819037 [TBL] [Abstract][Full Text] [Related]
15. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification. Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419 [TBL] [Abstract][Full Text] [Related]
16. Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR. Souzaki R; Tajiri T; Higashi M; Kinoshita Y; Tanaka S; Kohashi K; Tsuneyoshi M; Taguchi T Pediatr Surg Int; 2008 Oct; 24(10):1095-100. PubMed ID: 18726105 [TBL] [Abstract][Full Text] [Related]
17. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304 [TBL] [Abstract][Full Text] [Related]
18. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy. Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185 [TBL] [Abstract][Full Text] [Related]
19. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Harvey H; Piskareva O; Creevey L; Alcock LC; Buckley PG; O'Sullivan MJ; Segura MF; Gallego S; Stallings RL; Bray IM Int J Cancer; 2015 Apr; 136(7):1579-88. PubMed ID: 25137037 [TBL] [Abstract][Full Text] [Related]